Related Experiment Video
Updated: Sep 12, 2025
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
First Report of Successful Rituximab Therapy in Idiopathic Sclerosing Mesenteritis
Indira Acharya1,2, Carey Field1,2, Mary E Clark2,3
1Department of Rheumatology, Dartmouth Hitchcock Medical Center, NH, Lebanon.
Abstract:
Sclerosing mesenteritis (SM) is a rare idiopathic fibroinflammatory disorder of the bowel mesentery adipose tissue. While the use of rituximab has been documented in IgG4-related SM, its effectiveness in idiopathic, IgG4-unrelated SM remains unknown. We present a case of idiopathic SM successfully managed with rituximab, suggesting that this treatment may be an option for patients who either have contraindications to or have not responded to current first-line therapies.
More Related Videos
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
07:12Targeting the Rat's Small Bowel: Long-Term Infusion into the Superior Mesenteric Artery
Published on: April 8, 2021